AKT1 and non-small cell lung carcinoma: Wei demonstrated that LPCAT1 was up-regulated in NSCLC cells and tissues, and promoted NSCLC progression via PI3K/AKT/MYC pathway, can be used as a target for the NSCLC treatment [23].